USP2 and cancer: Patients with higher expression levels of USP2 have better OS prognoses than those with lower expression levels of USP2 in three cancer types (ACC, KIRC, and PAAD), and better DFS prognoses in three cancer types (ACC, KIRC, and THCA) (Figure 5B, log-rank test, unadjusted P-value < 0.05).